Trial Profile
A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-Proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Aug 2021
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Apr 2012 Status of extension trial (NCT00248131) is discontinued as reported by ClinicalTrials.gov
- 09 Apr 2012 Status of extension trial (NCT00248131) is discontinued as reported by ClinicalTrials.gov
- 09 Apr 2012 The actual end date for the extension trial (NCT00248131) is now July 2006 as reported by ClinicalTrials.gov.